Spravato for Treatment-Resistant Depression: Is It Right for You?
Trying antidepressants without enough relief can be exhausting. You may wonder whether another treatment is worth pursuing or whether the lack of improvement says something about you. It does not mean you have failed. Spravato for treatment-resistant depression is an option for some adults, but suitability depends on a clinical assessment—not simply counting how many medicines you remember taking.
Spravato contains esketamine and is administered under supervision at a certified healthcare setting. An evaluation considers the diagnosis, previous treatment trials, medical risks, current safety needs, and whether the appointment schedule and follow-up plan are workable for you.
What does treatment-resistant depression mean?
Treatment-resistant depression, often shortened to TRD, commonly describes depression that has not responded adequately to at least two antidepressant treatment trials of adequate dose and duration. Definitions and operational criteria vary across research and coverage policies. It is a description of a treatment history, not a prediction that improvement is impossible.
In the TRANSFORM-2 esketamine trial, participants had nonpsychotic depression and a history of inadequate response to at least two antidepressants during the current episode. That research context helps explain why a clinician asks which medicines were used, for how long, and what happened—not just whether you disliked them.
A medication stopped quickly because of severe adverse effects is important information, but it is not identical to an adequate trial that did little for symptoms. Do not repeat or extend a medicine independently to meet an eligibility rule. Your clinician should interpret the history and discuss appropriate next steps.
What is Spravato approved to treat?
The current Spravato prescribing information includes TRD in adults, either as monotherapy or alongside an oral antidepressant. Monotherapy means the medicine can be used without an accompanying oral antidepressant for that indication when the clinician decides this is appropriate.
There is also a separate indication for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior; that use includes an oral antidepressant. These indications have different requirements and should not be merged into one rule.
Spravato is not approved for pediatric patients. It is not established as a treatment that prevents suicide or reduces suicidal ideation or behavior, and it does not replace hospitalization when needed. Do not stop an existing antidepressant because you have read about the monotherapy indication.
Who qualifies for Spravato? Start with the diagnosis
Before recommending an advanced treatment, a clinician may review whether the current diagnosis fully explains the symptoms. Sleep problems, physical health conditions, substance use, medication effects, and other mental health conditions can influence what looks like an inadequate treatment response.
Past periods of unusually elevated or irritable mood, increased activity, or a much lower need for sleep are important to mention. The NIMH information on bipolar disorder explains the importance of considering symptoms over time rather than looking only at the current depressive period.
This review is not a reason to dismiss what you have already endured. It helps avoid repeating the wrong approach or assuming that every persistent symptom should lead directly to Spravato. A comprehensive depression assessment can consider the wider treatment picture.
Spravato eligibility: medical risks to review
The label lists specific contraindications, including aneurysmal vascular disease or arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine, ketamine, or product ingredients. These terms refer to particular medical conditions; a clinician should clarify how your own history relates to them.
Other concerns require individualized risk assessment, such as blood-pressure or cardiovascular problems, a history of psychosis, substance-use concerns, relevant medications, and pregnancy or breastfeeding. A risk factor is not always the same thing as a formal contraindication, and a blog cannot decide which category applies to you.
Tell the team about all medications and substances you use and any previous adverse reaction. It is safer to discuss a concern openly than to withhold it because you fear being declined. A careful assessment may lead to proceeding, adjusting the wider plan, delaying treatment, or choosing another option.
What do Spravato treatment requirements involve?
Spravato is not a spray to take home and try occasionally. It involves supervised administration and monitoring for at least two hours afterward, with assessment of clinical stability before discharge. Sedation, dissociation, respiratory effects, and blood-pressure changes are among the reasons for this process.
For adult TRD, current labeling describes an initial four-week phase with twice-weekly treatment, followed by less frequent treatment according to the labeled phases and clinical response. Your clinician assesses benefit at the end of induction and decides whether further treatment is appropriate. The schedule is not something to change independently.
Plan transport and time away from responsibilities. You must not drive or operate machinery until the following day after restful sleep. Ask about the treatment location, the likely full visit duration, what happens after a missed appointment, and who can answer concerns between visits.
Insurance eligibility is not the same as clinical suitability
An insurer may ask for documentation beyond a general diagnosis of TRD. For example, Aetna's published Spravato policy includes prior authorization and specified treatment-history and symptom-documentation requirements for its applicable commercial plans. These are an example of one payer's policy, not universal medical rules.
Ask your insurer and the practice which policy applies to your exact plan and proposed treatment. Confirm the approved indication, location, covered services, and expected patient costs. Coverage approval does not guarantee benefit, and a clinician's recommendation does not itself guarantee payment.
Prepare medication names, approximate dates, doses when known, effects, and reasons for stopping. Include psychotherapy and other treatments. Missing records can be reconstructed with help; they are not a reason to guess or exaggerate your history.
What other options should be discussed?
Depending on the assessment, a clinician may consider optimizing or changing medication, adding an appropriate treatment, reviewing psychotherapy, or discussing other interventions. Therapy and counseling may remain relevant even when medication treatment is being reconsidered.
Sophroneo's mental health services include several forms of care. The presence of multiple options should support a conversation about fit, not a requirement to try every service or an assumption that the newest treatment is automatically best.
Tell the clinician what matters most to you: relief from particular symptoms, avoiding certain adverse effects, managing work or family commitments, affordability, or building a sustainable follow-up plan. These priorities belong alongside clinical evidence and safety considerations.
Bring these questions to an evaluation
Ask: “Which parts of my history support TRD, and is there anything we should reassess before choosing another treatment?” A good discussion should clarify the diagnosis and previous trials rather than simply attach a label.
Ask: “What benefits are realistic, what risks are most relevant to me, and how will we measure change?” Choose concrete goals as well as symptom assessments. Being able to prepare meals or concentrate during a conversation can help describe functioning without replacing a clinical rating scale.
Ask: “When will we review whether this is worthwhile, and what is the plan if it is not?” There should be room to reconsider treatment when benefits are insufficient, adverse effects are difficult, or the practical burden is too high.
Discussing Spravato with Sophroneo
Sophroneo Behavioral Health & TMS has locations in Powder Springs and Marietta, serving the Atlanta area. Contact the practice to discuss an evaluation, bring your treatment history, and confirm current service availability and location.
The purpose of the first conversation is not to prove that you deserve a particular medication. It is to understand what you have tried, what remains difficult, and which next step is appropriate for your circumstances.
Frequently asked questions
Do two unsuccessful antidepressants automatically make me eligible?
No. The adequacy of the trials, diagnosis, symptom pattern, medical risks, and current situation matter. Insurance policies can add their own documentation requirements. Eligibility and treatment selection need an individualized assessment.
Does treatment-resistant mean nothing will work?
No. It describes inadequate response to previous treatment, not certainty about future care. Reassessment can identify other options or a different approach. Hope should be realistic and individualized rather than tied to a guaranteed result from one medicine.
Should I wait for a Spravato appointment if I feel unsafe?
No. Call or text 988 in the United States for crisis support. If there is immediate danger or a life-threatening emergency, call 911. A routine treatment appointment does not replace urgent assessment or hospitalization when needed.
This article is educational and does not determine medication eligibility or provide an individualized treatment recommendation. Do not change prescribed medication without your treating clinician.
Comments